Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis.
L. W. Goff
No relevant relationships to disclose
R. B. Cohen
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
J. Berlin
Research Funding - Pfizer
C. Noberasco
No relevant relationships to disclose
H. Borghaei
No relevant relationships to disclose
C. Gallo-Stampino
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
E. Wang
Employment or Leadership Position - Pfizer
D. Hu Lowe
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
W. J. Levin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
F. G. De Braud
Honoraria - Pfizer
Research Funding - Pfizer